When many people read about the possible price point for Scenesse for EPP in the analyst / company reports, there was a collective sticker shock.
I'm not referring to the price of the drug in Italy, but the expected price of the drug if it gets formal FDA or EMA approval.
I had felt that it's one thing to price the drug to ensure a profit, but I wondered if it was really necessary to price the drug as high as some of the price points we've seen.
Now KV Pharmaceuticals, a stock that I got in at around $1.75 earlier this year to witness a 12 bagger (went over $13 a month later), is going to be investigated for price gouging if U.S. Senator Brown has his way.
Biotechs and pharmas cannot just price a drug at whatever price point they choose. It's a different industry than most other free market industries.
We're not sure what price point Clinuvel will select upon approval, but I hope they keep this in mind. In this day and age, it's much easier to mobolize a grassroots effort to get the attention of legislators.
- Forums
- ASX - By Stock
- interesting pricing gouging case
When many people read about the possible price point for...
-
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CUV (ASX) to my watchlist
|
|||||
Last
$14.55 |
Change
-0.170(1.15%) |
Mkt cap ! $728.6M |
Open | High | Low | Value | Volume |
$15.00 | $15.00 | $14.27 | $1.051M | 72.59K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 293 | $14.40 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.59 | 293 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 293 | 14.400 |
1 | 293 | 14.370 |
1 | 293 | 14.350 |
1 | 293 | 14.320 |
3 | 1582 | 14.290 |
Price($) | Vol. | No. |
---|---|---|
14.590 | 293 | 1 |
14.610 | 293 | 1 |
14.640 | 293 | 1 |
14.670 | 1584 | 4 |
14.950 | 500 | 1 |
Last trade - 16.10pm 09/09/2024 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |